NYSEAMERICAN:SYNSynthetic Biologics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Synthetic Biologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.54 +0.03 (+5.50 %) (As of 07/9/2020 04:00 PM ET) Add Compare Share Today's Range$0.51Now: $0.54▼$0.5450-Day Range N/A52-Week Range$0.25Now: $0.54▼$0.64Volume92,400 shsAverage Volume376,669 shsMarket Capitalization$9.88 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Synthetic Biologics, Inc., a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates include SYN-004 that is in Phase III clinical trial designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases, and monoclonal antibody therapies that prevents and treats pertussis. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSynthetic Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.38, Synthetic Biologics has a potential upside of 154.1% from its current price of $0.54.Amount of Analyst CoverageSynthetic Biologics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesSynthetic Biologics has received 469 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSynthetic Biologics has received 386 “underperform” votes. (Add your “underperform” vote.)Community SentimentSynthetic Biologics has received 54.85% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote “Outperform” if you believe SYN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SYN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSynthetic Biologics does not currently pay a dividend.Dividend GrowthSynthetic Biologics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Synthetic Biologics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.24 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:SYN Previous Symbol CUSIPN/A CIK894158 Webwww.syntheticbiologics.com Phone+1-734-3327800Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees13 Outstanding Shares18,264,000Market Cap$9.88 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable AMEX:SYN Rates by TradingView Receive SYN News and Ratings via Email Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter. Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Synthetic Biologics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Synthetic Biologics. When is Synthetic Biologics' next earnings date? Synthetic Biologics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Synthetic Biologics. How were Synthetic Biologics' earnings last quarter? Synthetic Biologics Inc (NYSEAMERICAN:SYN) posted its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.07. View Synthetic Biologics' earnings history. When did Synthetic Biologics' stock split? How did Synthetic Biologics' stock split work? Synthetic Biologics's stock reverse split on Monday, August 13th 2018. The 1-35 reverse split was announced on Wednesday, August 1st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 10th 2018. An investor that had 100 shares of Synthetic Biologics stock prior to the reverse split would have 3 shares after the split. What price target have analysts set for SYN? 2 brokerages have issued 12 month price targets for Synthetic Biologics' stock. Their forecasts range from $1.25 to $1.50. On average, they anticipate Synthetic Biologics' stock price to reach $1.38 in the next year. This suggests a possible upside of 154.1% from the stock's current price. View analysts' price targets for Synthetic Biologics. Has Synthetic Biologics been receiving favorable news coverage? Media stories about SYN stock have trended negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Synthetic Biologics earned a daily sentiment score of -2.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Synthetic Biologics. Who are some of Synthetic Biologics' key competitors? Some companies that are related to Synthetic Biologics include Quest PharmaTech (QPT), Ceapro (CZO), Actinogen Medical (ACW), Exopharm (EX1), Galena Biopharma (SLS), AorTech International (AOR), BTC Health (BTC), C4X Discovery (C4XD), Regeneus (RGS), Nyrada (NYR), Cellmid (CDY), Prescient Therapeutics (PTX), Inhibitor Therapeutics (INTI), Nuformix (NFX) and Agronomics (ANIC). View all competitors. What other stocks do shareholders of Synthetic Biologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synthetic Biologics investors own include Synergy Pharmaceuticals (SGYP), Tonix Pharmaceuticals (TNXP), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Agenus (AGEN), Protalix Biotherapeutics (PLX), ACADIA Pharmaceuticals (ACAD), Actinium Pharmaceuticals (ATNM), Energy Transfer LP Unit (ET) and Gilead Sciences (GILD). Who are Synthetic Biologics' key executives? Synthetic Biologics' management team includes the following people: Mr. Steven A. Shallcross CPA, CEO, CFO, Treasurer, Corp. Sec. & Director (Age 58)Vincent I. Perrone, Director of Corp. CommunicationDr. Vince Wacher, Head of Product and Corp. Devel.Dr. Michael Kaleko, Sr. VP of R&DDr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing What is Synthetic Biologics' stock symbol? Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN." How do I buy shares of Synthetic Biologics? Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Synthetic Biologics' stock price today? One share of SYN stock can currently be purchased for approximately $0.54. How big of a company is Synthetic Biologics? Synthetic Biologics has a market capitalization of $9.88 million. Synthetic Biologics employs 13 workers across the globe. What is Synthetic Biologics' official website? The official website for Synthetic Biologics is www.syntheticbiologics.com. How can I contact Synthetic Biologics? Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800. This page was last updated on 7/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
